Clinical trial NCT02242006: Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)
Official title: Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Critical Illness
Kidney Injury
Pharmacokinetics
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
First posted: 2014-09-16
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: critically ill adults admitted to an ICU

Brief summary: Severe acute kidney injury (AKI) is a common complication of critical illness affecting almost half of all patients with septic shock. Extracorporeal renal replacement therapy is a cornerstone in the management of AKI in these patients. Options for renal replacement therapy include continuous renal replacement (CRRT) therapy, intermittent dialysis (IHD) or a hybrid form of the two called sustained low efficiency dialysis (SLED). Globally there is a push to switch from traditional CRRT to SLED. Although there are resource and financial comparative benefits to SLED there is almost no literature describing how to dose antimicrobials (or other drugs for that matter). It appears that drug clearance on SLED may be more efficient than CRRT but not as efficient as IHD making extrapolation from these bodies of literature inappropriate for SLED. The investigators are proposing to conduct the population pharmacokinetic studies for the three most commonly used antimicrobials in critically ill patients receiving SLED therapy (piperacillin-tazobactam, meropenem and vancomycin). Population pharmacokinetic modeling of these drugs will provide estimates and sources of variability around pharmacokinetic parameters that will subsequently be used for Monte Carlo simulation to determine the most appropriate dosing regimens to achieve therapeutic targets while minimizing the risk of toxicity.


Eligibility criteria: Inclusion Criteria:

* Critically ill adults \[age ≥ 18\] admitted to one of two of the medical/surgical intensive care units (ICUs) of The Ottawa Hospital, who require SLED and are or will receive meropenem, piperacillin-tazobactam or vancomycin therapy at any dose.

Exclusion Criteria:

* Patients for whom participation via the informed consent process is denied.
* Critically ill patients with a hypermetabolic state due to \>25% coverage of body surface area burn, cystic fibrosis, spinal cord injury, bariatric patients (defined as \>150kg total body weight)
* Patient is pregnant as per a positive serum or urine βHCG qualitative assay
* Patient does not have a closed-system arterial or central venous catheter (to minimize blood wastage)
* Patients receiving concomitant drugs known to interact with the metabolism or clearance of the antimicrobial of interest according to Micromedex 2.0 (Truven Health Analytics Inc 2013)

Primary outcomes:
measure: drug clearance
timeFrame: During the first run of SLED after study inclusion
measure: volume of distribution
timeFrame: During the first run of SLED after study inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Ottawa
country: Canada
facility: The Ottawa Hospital
state: Ontario
Study officials:
References: